Global General Anesthesia Drugs Market Size (2024 - 2029)

General Anesthesia Drugs Market Analysis

The Global General Anesthesia Drugs Market size is estimated at USD 5.28 billion in 2024, and is expected to reach USD 6.25 billion by 2029, growing at a CAGR of 3.59% during the forecast period (2024-2029).

The primary goal of general anesthesia is to make a patient unconscious and not feel pain during the surgical procedure. The increasing prevalence of diseases such as cancer, cardiovascular diseases, arthritis, and others among the population raises the need for effective management of the disease through pharmaceuticals, physical therapy, and surgeries, which in turn fuel the demand for general anesthesia drugs to render a patient unconscious and unable to feel painful stimuli while controlling autonomic reflexes during surgeries.

The increasing burden of cancer among the population raises the demand for treatment through a surgical intervention that involves removing cancer cells and lymph nodes that are affected. Hence, the market growth of general anesthesia drugs used in such procedures is anticipated to augment over the forecast period. For instance, according to 2024 statistics published by the American Cancer Society, about 2 million new cancer cases are expected to be diagnosed in the United States in 2024, compared to 1.92 million new cancer cases in 2023.

Furthermore, according to the National Adult Cardiac Surgery Audit Report 2023, the number of adult heart operations in 2022 was 24,807 compared to 19,333 in 2021. This, in turn, is expected to fuel the demand for general anesthesia drugs used in such procedures over the forecast period. Moreover, according to the World Health Organization, in 2022, it was mentioned that by 2030, one in six people in the world would be aged 60 years, and by 2050, the world’s population of people aged 60 years and older would double to 2.1 billion. Therefore, as the senior population is more prone to various chronic diseases and further surgeries, the need for general anesthesia drugs elevates, leading to market growth over the forecast period.

Moreover, increase in advanced general anesthesia product launches and the approvals of pipeline products by regulatory agencies such as the US Food and Drug Administration (FDA), Brazilian Health Regulatory Agency (ANVISA), European Medicines Agency (EMA), Therapeutic Goods Administration (TGA) among others, are expected to fuel the market’s growth over the forecast period. For instance, in October 2022, Hikma launched Succinylcholine Chloride, an important medicine used in hospitals for general anesthesia, to facilitate tracheal intubation, and to provide muscle relaxation during surgery or mechanical ventilation in the form of an injection in a prefilled syringe form in the United States.

Therefore, factors such as the rising number of surgeries for chronic diseases raise the demand for general anesthesia drugs, driving the market’s growth during the forecast period. However, risks associated with general anesthesia in pediatric patients and pregnant women may likely impede market growth.

General Anesthesia Drugs Industry Segmentation

The general anesthesia drugs market is segmented by type of drugs, route of administration, surgery type, end user, and geography. By type of drugs, the market is segmented into Sevoflurane, Desflurane, Isoflurane, Nitrous Oxide, Propofol, and Other Drugs. By route of administration, the market is segmented into inhalation and intravenous. The market is segmented by surgery type into general surgery, cancer surgery, heart surgery, knee and hip replacements, and other surgery types. End users segment the market into hospitals, ambulatory surgical centers, and other end users. The market also covers estimated market size and trends in 17 major world regions. The report offers the market size in value terms in USD for all the abovementioned segments.